Context Therapeutics (CNTX) Cash & Equivalents (2020 - 2026)

Context Therapeutics has reported Cash & Equivalents for 7 years, with the latest figure at $54.5 million in Q1 2026.

• Quarterly Cash & Equivalents fell 38.97% year-over-year to $54.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $54.5 million (down 38.97% YoY) and the FY2025 annual result came in at $66.0 million, down 30.11% from the prior year.
• Cash & Equivalents retreated to $54.5 million in Q1 2026 per CNTX's latest filing, from $66.0 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $101.5 million in Q2 2024 and troughed at $10.1 million in Q1 2024.
• A 5-year average of $53.9 million and a median of $45.7 million in 2022 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2024: Cash & Equivalents soared 9750.0% in 2022, then slumped 66.11% in 2024.
• Over 5 years, Cash & Equivalents stood at $35.5 million in 2022, then sank by 59.29% to $14.4 million in 2023, then surged by 553.5% to $94.4 million in 2024, then slumped by 30.11% to $66.0 million in 2025, then fell by 17.37% to $54.5 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $54.5 million, $66.0 million, and $76.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.